

# COVID 19



Keeping Up with a Moving Target



# CME Information

**Jointly provided by Postgraduate Institute for Medicine, DKBmed, and the Institute for Johns Hopkins Nursing.**

## Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter	Reported Financial Relationship
Paul G. Auwaerter, MD, MBA, FIDSA	JNJ: Ownership equity Scientific Consulting: Verily, EMD Serono DMSB: Humanigen

Dr. Auwaerter has indicated that he will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials, including monoclonal antibodies and vaccines.

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.



## CME Information

**To attest for CME/CE/AAPA credit, please visit**  
**[COVID19.dkamed.com](https://COVID19.dkamed.com)**



# Learning Objectives

- Discuss the current state of COVID-19 vaccination



## Thank You

This activity is supported by educational grants from Gilead Sciences, Inc., Regeneron Pharmaceuticals, and Eli Lilly and Company.

All activity content and materials have been developed solely by the activity directors, planning committee members, and faculty presenters.

Please see **COVID19.DKBmed.com** for additional resources and educational activities



**Paul Auwaerter, MD, MBA, FIDSA**

Clinical Director, Division of Infectious Diseases

Sherrilyn and Ken Fisher Professor of Medicine

Fisher Center for Environmental Infectious Diseases

Johns Hopkins University School of Medicine





# The Hill - CDC Has to Get the Messaging Right with the COVID-19 Vaccine

CRISIS RESPONSE , FACULTY IN THE MEDIA

[News](#)
[Policy](#)
[Opinion](#)
[Events](#)
[Jobs](#)
[HILL.TV](#)
[Changing America](#)
[Coronavirus Report](#)
[f](#)
[t](#)
[in](#)

TRENDING: CORONAVIRUS ROGER STONE RUSSIAN BOUNTIES DONALD TRUMP JOE BIDEN



## CDC has to get the messaging right with the COVID-19 vaccine

BY DR. JANICE BLANCHARD, OPINION CONTRIBUTOR — 07/14/20 06:00 PM EDT  
THE VIEWS EXPRESSED BY CONTRIBUTORS ARE THEIR OWN AND NOT THE VIEW OF THE HILL

105 COMMENTS

170 SHARES



Just In...



# Vaccine Availability

ctions ☰

The Washington Post  
Democracy Dies in Darkness

Coronavirus U.S. map World map Vaccine tracker Vaccine FAQ Variants FAQ A pandemic year Coronavirus Living

● Covid-19 live updates

## Biden urges vaccinations for all adults – ‘Everybody is eligible as of today’

April 19, 2021 COVID-19 Vaccinations in the United States

Overall US COVID-19 Vaccine | Deliveries and Administration; Maps, charts, and data provided by CDC, updates daily by 8 pm ET<sup>†</sup>  
Represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

Total Vaccine Doses		People Vaccinated	
		At Least One Dose	Fully Vaccinated
Delivered	264,505,725	Total	132,321,628
Administered	211,581,309	% of Total Population	39.9%
Learn more about the distribution of vaccines.		Population ≥ 18 Years of Age	130,995,636
		% of Population ≥ 18 Years of Age	50.7%
		Population ≥ 65 Years of Age	43,826,574
		% of Population ≥ 65 Years of Age	80.1%
		Total	85,365,180
		% of Total Population	25.7%
		Population ≥ 18 Years of Age	85,060,671
		% of Population ≥ 18 Years of Age	33%
		Population ≥ 65 Years of Age	35,478,824
		% of Population ≥ 65 Years of Age	64.9%


[About these data](#)

CDC | Data as of: April 19, 2021 6:00am ET. Posted: Monday, April 19, 2021 4:42 PM ET

~ 3.3 million doses/day



# US Population with Completed COVID-19 Vaccine





# Janssen/J&J Vaccine: Decision Soon Regarding Use

CDC Centers for Disease Control and Prevention  
CDC 24/7: Saving Lives. Protecting People™

Search COVID-19

## COVID-19



- Your Health
- Vaccines**
- Cases & Data
- Work & School
- Healthcare Workers
- Health Depts
- Science
- More

### Vaccines

- Key Things to Know +
- Benefits of Getting Vaccinated
- Information for Different Groups +
- Find a Vaccine
- Your Vaccination +
- Different Vaccines +
- Vaccine Safety & Monitoring** -

## Recommendation to Pause Use of Johnson & Johnson's Janssen COVID-19 Vaccine

Updated Apr. 16, 2021 Languages Print

On April 13, 2021, CDC and FDA recommended a pause in the use of Johnson & Johnson's Janssen COVID-19 Vaccine. Of the nearly 7 million doses administered so far in the United States, a small number of reports of a rare and severe type of blood clot have been reported in people after receiving the J&J/Janssen COVID-19 Vaccine. All reports occurred among women between the ages of 18 and 48, and symptoms occurred six to 13 days after vaccination. As of April 13, 2021, of the more than 180 million doses administered so far of the Pfizer-BioNTech or Moderna vaccines, no reports matching those associated with the J&J/Janssen vaccine have been received.

Get answers to your questions



# When will US Pandemic Restrictions be Lifted?

Hard to pin down, but here are some factors to watch

1. Low community rates, 5-10 per 100,000 of population (or 10,000-16,000 cases)

Especially if percentage needed hospitalization declines lower

Current US figure ~ 70,000 cases/day

2. COVID-19 hospitalizations

Among the easiest to understand and track

~ 700 deaths/day

3. Viral reproduction number appears reliably low ( $R < 1.0$ )


4. Percentage of people immunized

Easier to track and understand than including natural immunity

# US: When will Herd Immunity Occur?

**Earlier peak, longer tail: Q3 now likelier for herd immunity, given vaccine availability, but variants of concern could prolong the end.**

Probability of herd immunity<sup>1</sup> to COVID-19 for UK and US<sup>2</sup> by quarter (illustrative)





**To submit your own question, please email [QA@dkbmed.com](mailto:QA@dkbmed.com)**



**When do you think vaccines will be authorized for young children?**





**What is the status of molnupiravir? Do you think it looks promising?**



# Thank You!

**To receive CME/CE/AAPA credit:**

Complete the evaluation on at [COVID19.DKBmed.com](https://COVID19.DKBmed.com)

Upon registering and successfully completing the activity evaluation, you will have immediate access to your certificate.

**To access more resources related to COVID-19:**

- Access our resource hub at [COVID19.DKBmed.com](https://COVID19.DKBmed.com)

**To ask your own question, email:**

- [QA@dkbmed.com](mailto:QA@dkbmed.com)